research use only

Ethambutol 2HCl Bacterial chemical

Cat.No.S4004

Ethambutol 2HCl (CL40881) is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.
Ethambutol 2HCl Bacterial chemical Chemical Structure

Chemical Structure

Molecular Weight: 277.23

Quality Control

Batch: S400401 DMSO]56 mg/mL]false]Water]56 mg/mL]false]Ethanol]Insoluble]false Purity: 100%
100

Chemical Information, Storage & Stability

Molecular Weight 277.23 Formula

C10H24N2O2.2HCl

Storage (From the date of receipt)
CAS No. 1070-11-7 -- Storage of Stock Solutions

Synonyms CL40881 Smiles CCC(CO)NCCNC(CC)CO.Cl.Cl

Solubility

In vitro
Batch:

DMSO : 56 mg/mL ( (201.99 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 56 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
Ethambutol directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants. [1] Ethambutol is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. [1] Ethambutol is potency against M. tuberculosis (H37Rv) with MIC of 0.5 μg/mL in vitro. [2] Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 μg/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 μg/mL and 0.18 μg/mL, respectively. [3]
In vivo
Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 ×/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07). [3]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05840809 Recruiting
Tuberculosis Active|Breastfeeding|Tuberculosis
University of Liverpool|Infectious Diseases Institute Makerere University College of Health Sciences
January 20 2022 --
NCT04972903 Unknown status
Tuberculosis|Pulmonary
Institut National de la Santé Et de la Recherche Médicale France|National Agency for Research on AIDS and Viral Hepatitis (ANRS)
August 2021 --
NCT02114684 Completed
Recurrent Tuberculosis
Centre for the AIDS Programme of Research in South Africa
November 2013 Phase 1|Phase 2
NCT02496572 Unknown status
Multidrug Resistant Tuberculosis
Medecins Sans Frontieres Netherlands|Ministry of Health Republic of Uzbekistan|Imperial College London
September 2013 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.